Advances in nanomedicine strategies for modulating the tumor microenvironment: Recent progress and clinical perspectives
3 Biotech · 2026-01 · 16 (1)
DOI: 10.1007/s13205-025-04651-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift 3 Biotech, online erschienen am 20.12.2025. Verfasst von Talha Bin Emran und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40202 USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 339 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The tumor microenvironment (TME) significantly impacts tumor development, metastasis, immune evasion, and resistance to conventional treatments. Recent nanomedicine advancements aid the formation of intelligent, multipurpose nanosystems that precisely target and modify various TME elements, including hypoxia, extracellular matrix, tumor-associated macrophages, and immunological checkpoints. The review highlights recent advancements in nanotechnology-based methods for optimizing medication delivery, renewing the TME, and enhancing treatment outcomes. It discusses the impact of nanomedicines on the TME, including immune modulation, stimuli-responsive drug release, and the restoration of abnormal vasculature. It also demonstrates the translational landscape of these methods, focusing on safety profiles, clinical trials, and scaling challenges from preclinical models to clinical applications. Nanomedicine offers personalized cancer treatments by regulating tumor TME, enhancing immunity, restoring tumor vasculature, and targeting multiple TME components through smart nanocarriers. Combination approaches with immunotherapy, photothermal therapy, and chemotherapy show synergistic results. Clinical trials show promise but face scalability and reproducibility issues.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40202 USA.
- Department of Pharmacy, Faculty of Health and Life Sciences, Daffodil International University, Dhaka, 1216 Bangladesh.
- Department of Clinical Laboratory Sciences, College of Applied Medical Science, King Khalid University, Abha, Saudi Arabia.
- Wishmen Lifesciences Pvt Ttd, Banjara Hills, Hyderabad, Khairatabad, Telangana, India.
- Department of Pharmaceutics, School of Pharmacy, Anurag University, Hyderabad, Telangana 500088 India.
- Institute of Pharmaceutical Research, GLA University Mathura, Uttar Pradesh, India.
ORCID-Profile: Talha Bin Emran
Zitieren
APA
Emran, T. B., Al Amin, M., Rab, S. O., Jahnavi, P., Vodeti, R., Gupta, J. K., Arjun, U. V. N. V., Umamaheswari, T. N., Balaji, P., Dayalan, G., Rani, S., & Gupta, P. S. (2026). Advances in nanomedicine strategies for modulating the tumor microenvironment: Recent progress and clinical perspectives. 3 Biotech, 16(1). https://doi.org/10.1007/s13205-025-04651-5
Vancouver
Emran TB, Al Amin M, Rab SO, Jahnavi P, Vodeti R, Gupta JK, et al. Advances in nanomedicine strategies for modulating the tumor microenvironment: Recent progress and clinical perspectives. 3 Biotech. 2026;16(1). doi:10.1007/s13205-025-04651-5
BibTeX
@article{Emran2026,
author = {Emran, Talha Bin and Al Amin, Md and Rab, Safia Obaidur and Jahnavi, Patibandla and Vodeti, Rajeshwar and Gupta, Jeetendra Kumar and Arjun, Uppuluri Varuna Naga Venkata and Umamaheswari, T N and Balaji, P and Dayalan, Girija and Rani, Soniya and Gupta, Prem Shankar},
title = {Advances in nanomedicine strategies for modulating the tumor microenvironment: Recent progress and clinical perspectives},
journal = {3 Biotech},
year = {2026},
volume = {16},
number = {1},
doi = {10.1007/s13205-025-04651-5}
}
EUVIMED